Webinar: Targeted Treatment Strategies for Advanced Cholangiocarcinoma -Results of Promising Trials

Dr. Lipika Goyal provides an overview of the actionable targets in cholangiocarcinoma, including data from the FOENIX-CCA2 study, for the use of futibatinib, an irreversible pan-FGFR inhibitor, in advanced cholangiocarcinoma. Dr. Volker Wacheck (Taiho Oncology) also provides an overview of the Expanded Access Study (NCT04507503) of futibatinib in cholangiocarcinoma.
Recorded 9/29/2022